Posted on 02/18/21
| News Source: i24
Laboratory study found that shot provided a two-thirds reduction in level of neutralizing antibodies
Pfizer Inc/BioNTech SE announced that a laboratory study suggests that the South African variant of the coronavirus may reduce antibody protection from their vaccine by up to two-thirds, and it is not clear if the shot will be effective against the mutation, reported Reuters.
Join BJL on WhatsApp Status: Click here to Join BJL status for engagements, births, deals, levayos, events & more
Join BJL on WhatsApp Groups: Click here to Join an official BJL WhatsApp group for breaking news as it happens
The study found the vaccine was still able to neutralize the virus and there is not yet evidence from trials in people that the variant reduces vaccine protection, the companies said.
They are making investments and talking to regulators about developing an updated version of their mRNA vaccine or a booster shot, if needed. Read more at i24